Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Mainz Biomed B.V. MYNZ
$5.17
-$0.08 (-1.58%)
На 18:05, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
67609296.00000000
-
week52high
12.40
-
week52low
3.18
-
Revenue
529877
-
P/E TTM
0
-
Beta
0.00000000
-
EPS
-1.76000000
-
Last Dividend
0.00000000
-
Next Earnings Date
16 мая 2023 г. в 13:01
Описание компании
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Mainz Biomed: A Long-Term Bet Relying On Expanded Testing
Seeking Alpha
30 окт 2022 г. в 02:16
Mainz Biomed is a German developer of genetic tests for various diseases, primarily cancer. At the moment, the company has one main product, ColoAlert, a colorectal cancer test that is so far only approved in some non-US countries.
Mainz Biomed to Present at the H.C. Wainwright Annual Global Investment Conference
GlobeNewsWire
01 сент 2022 г. в 03:01
BERKELEY, Calif. and MAINZ, Germany, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that Bill Caragol, Chief Financial Officer, will present at the H.C. Wainwright Annual Global Investment Conference taking place from September 12-14, 2022.
Mainz Biomed to Participate in H.C. Wainwright Global Investment Conference and Equity Forum German Spring Conference
GlobeNewsWire
17 мая 2022 г. в 03:01
BERKELEY, Calif. and MAINZ, Germany, May 17, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that members of its executive team will be participating in two notable investor conferences in May, 2022, the H.C. Wainwright Global Investment Conference and the Equity Forum German Spring Conference.
Why Mainz Biomed Stock Is Crashing Today
The Motley Fool
26 янв 2022 г. в 12:36
The molecular genetics diagnostic company announced the pricing of a follow-on stock offering.
Mainz Biomed: Sharp Appreciation In Value Since IPO
Seeking Alpha
26 янв 2022 г. в 06:17
Mainz Biomed has filed Form F-1 to raise ~$41 million gross proceeds from 1.5M shares.